Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER-2 Positive Breast Cancer
Interventions: DRUG: Trastuzumab|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Carboplatin
Sponsor: Zhimin Shao
Collaborators: Roche Pharma AG